Aclaris Therapeutics, Inc. Overview
Pro stress-test →Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases. The company is advancing a multi-program pipeline targeting significant unmet needs in dermatology and immunology with both small-molecule and biologic candidates.
Strategic Profile
Pro stress-test →The company achieved strong business execution in 2025 with continued momentum across programs, and 2026 has started with derisking events for two key programs (ITK and ATI-052). Aclaris maintains a strong cash position with several meaningful catalysts expected across its biologics and ITK pipeline this year.
Competitive Landscape
Pro stress-test →Aclaris competes in the immuno-inflammatory therapeutics space against companies developing JAK inhibitors, monoclonal antibodies, and ITK inhibitors. Key competitive programs include ritlecitinib (Pfizer, alopecia areata) and various TSLP-targeting biologics. Aclaris differentiates through its bispecific ATI-052 platform combining dual pathway inhibition and its proprietary ITK-selective inhibitor technology.
Industry Context
Aclaris Therapeutics, Inc. operates in Biopharmaceuticals - Immuno-inflammatory Therapeutics.
Key facts
Founded: 2016 · Headquarters: Wayne, PA · Revenue: $1.30M · Market cap: $339.14M